



JPW/1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Applicant: Kipriyanov, et al.

Application No.: 10/510,881

Date Filed: April 21, 2005

Title: ANTIBODY COMBINATION
USEFUL FOR TUMOR
THERAPY

Docket No.: 4121-172

Examiner: Unassigned

Art Unit: 1646


Conf. No.: 6340

Customer No.:

23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.


Joanna Joslyn

June 8, 2005
Date of Mailing

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuierer
Reg. No. 39,983
Attorney for Applicant

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4121-172



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 3

COMPLETE IF KNOWN


Application Number	10/510,881
Filing Date	April 21, 2005
First Named Inventor	KIPRIYANOV, et al.
Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	4121-172

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AB	Adams, Gregory P., et al., <i>Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies</i> , <u>Cancer Research</u> , vol 58, 1998, pp. 485-490.	
	AC	Arndt, Michaela A.E., et al., <i>A Bispecific Diabody that Mediates Natural Killer Cell Cytotoxicity Against Xenotransplanted Human Hodgkin's Tumors</i> , <u>Blood</u> , vol 94, 1999, pp. 2562-2568.	
	AD	Benedict, Chris A., et al., <i>Determination of the Binding Affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry assay</i> , <u>Journal of Immunological Methods</u> , vol 201, 1997, pp. 223-231.	
	AE	Broglie, Richard, et al., <i>Light-Regulated Expression of a Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells</i> , <u>Science</u> , vol 224, 1984, pp. 838-843.	
	AF	Cochlovius, Björn, et al., <i>Treatment of Human B Cell Lymphoma Xenografts with a CD3 x CD19 Diabody and T Cells</i> , <u>The Journal of Immunology</u> , 2000, pp. 888-895.	
	AG	da Costa, Ligia, et al., <i>Immune Recruitment by Bispecific Antibodies for the Treatment of Hodgkin Disease</i> , <u>Cancer Chemother Pharmacol</u> , vol 46, 2000, (Suppl), S33-S36.	
	AH	Engelhard, E.K., et al., <i>The Insect Tracheal System: A Conduit for the Systemic Spread of Autographa Californica M Nuclear Polyhedrosis Virus</i> , <u>Proc. Natl. Acad. Sci.</u> vol 91, 1994, pp. 3224-3227.	
	AI	Hartman, Standish C., et al., <i>Two Dominant-Acting Selectable Markers for Gene Transfer Studies in Mammalian Cells</i> , <u>Proc. Natl. Acad. Sci.</u> vol 85, 1988, pp. 8047-8051.	
	AJ	Kipriyanov, Sergey, et al., <i>Bispecific CD3x CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells</i> , <u>Int. J. Cancer</u> vol 77, 1998, pp. 763-772.	
	AK	Kipriyanov, Sergey, et al., <i>Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics</i> , <u>J. Mol. Biol.</u> vol 293, 1999, pp. 41-56.	
	AL	Kipriyanov, Sergey, et al., <i>Synergistic Antitumor Effect of Bispecific CD19 x CD3 and CD19 x CD16 Diabodies in a Preclinical Model of Non-Hodgkin's Lymphoma</i> , <u>J. Immunology</u> , 2002, pp. 137-144.	
Examiner signature			Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).



**INFORMATION
DISCLOSURE STATEMENT
BY APPLICANT**

Sheet 3 of 3

COMPLETE IF KNOWN

Application Number	10/510,881
Filing Date	April 21, 2005
First Named Inventor	KIPRIYANOV, et al.
Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	4121-172

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AM	Kipriyanov, Sergey, et al., <i>Novel Recombinant Bispecific Molecules for Immunotherapy of Blood Malignancies</i> , <u>Int. J. Cancer</u> vol 77, 2001, pp. 763-772.	
	AN	Kudo, Toshio, et al., <i>Specific Targeting Immunotherapy of Cancer with Bispecific Antibodies</i> , <u>J. Exp. Med.</u> , vol. 188, 1999, 275-288.	
	AO	Logan, John, et al., <i>Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late after Infection</i> , <u>Proc. Natl. Acad. Sci.</u> vol 81, 1984, 3655-3659.	
	AP	Lowy, Israel, et al., <i>Isolation of Transforming DNA: Cloning the Hamster aprt Gene</i> , <u>Cell</u> vol 22, 1980, 817-823.	
	AQ	Matzinger, Polly, <i>The JAM Test: A Simple Assay for DNA Fragmentation and Cell Death</i> , <u>Journal of Immunological Methods</u> vol 145, 1991, 185-192.	
	AR	Pezzutto, Antonio, et al., <i>CD19 Monoclonal Antibody HD37 Inhibits Anti-Immunoglobulin-Induced B Cell Activation and Proliferation</i> , <u>Journal of Immunology</u> vol 138, 1987, 2793-2799.	
	AS	Renner, Christoph, et al., <i>Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells</i> , <u>Science</u> vol 264, 1994, 833-835.	
	AT	Wigler, Michael, et al., <i>Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells</i> , <u>Cell</u> vol 11, 1977, 223-232.	
	AU	Wigler, Michael, et al., <i>Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene</i> , <u>Proc. Natl. Acad. Sci.</u> vol 77, 1980, 3567-3570.	
	AV	Zimmerman, Lyle, et al., <i>Independent Regulatory Elements in the Nestin Gene Direct Transgene Expression to Neural Stem Cells or Muscle Precursors</i> , <u>Neuron</u> vol 12, 1994, 11-24.	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).